Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Rating of “Moderate Buy” from Brokerages

Kura Oncology, Inc. (NASDAQ:KURA) has received an average rating of “Moderate Buy” from the twelve ratings firms that are covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $27.13.

A number of analysts have recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research report on Monday, December 9th. HC Wainwright boosted their price objective on Kura Oncology from $37.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, February 6th. Bank of America lowered their price target on Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a research report on Friday, November 22nd. Scotiabank lowered their price target on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 8th. Finally, BTIG Research cut Kura Oncology from a “buy” rating to a “neutral” rating in a research report on Thursday, February 6th.

Insider Transactions at Kura Oncology

In other news, insider Mollie Leoni sold 4,963 shares of the company’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the transaction, the insider now owns 88,253 shares of the company’s stock, valued at $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the transaction, the senior vice president now directly owns 88,193 shares in the company, valued at $694,078.91. This trade represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 11,729 shares of company stock worth $92,307. Insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

Large investors have recently made changes to their positions in the company. nVerses Capital LLC acquired a new position in shares of Kura Oncology during the third quarter valued at $25,000. Virtus ETF Advisers LLC lifted its stake in shares of Kura Oncology by 71.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock valued at $64,000 after acquiring an additional 3,061 shares during the period. Point72 DIFC Ltd acquired a new position in Kura Oncology in the third quarter valued at about $146,000. Harbor Advisors LLC acquired a new position in Kura Oncology in the fourth quarter valued at about $87,000. Finally, E Fund Management Co. Ltd. acquired a new position in Kura Oncology in the fourth quarter valued at about $90,000.

Kura Oncology Stock Performance

KURA opened at $8.28 on Tuesday. The stock has a market cap of $643.85 million, a PE ratio of -3.51 and a beta of 0.78. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a 1 year low of $6.98 and a 1 year high of $24.17. The stock’s 50 day simple moving average is $8.44 and its 200-day simple moving average is $14.43.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.